The initiation of an Expanded Access Program for Plozasiran by Arrowhead Pharmaceuticals is a significant step towards bringing the drug to patients outside of clinical trials. This move not only demonstrates Arrowhead's commitment to patient care but also has the potential to accelerate the drug's market penetration and usage. Such developments are often viewed positively by investors as they can lead to increased adoption and sales of the drug, thereby potentially boosting the company's stock price in the short term.